Sciex Collaborate on Major Proteomic Mapping Project
Sciex has announced that it will work with the Francis Crick Institute and the University of Cambridge to build a metabolism-centric proteomic map.
Sciex (Massachusetts, USA) has announced that it will work with the Francis Crick Institute (London, UK) and the University of Cambridge (Cambridge, UK) to build a metabolism-centric proteomic map.
The comprehensive map will focus on enzymes involved in the control of metabolism and will be developed using Sciex micro-flow chromatography and data-independent Swath acquisition.
David Roblin, Chief Operating Officer and Director of Scientific Translation at the Francis Crick Institute, expressed delight at the collaboration and highlighted the support received from the Biotechnology and Biological Sciences Research Council (BBSRC) UK. “The grant from the BBSRC demonstrates that the multidisciplinary nature of the Crick is creating new scientific ideas that are leading to translation and commercial opportunities. This accelerated translation of our science for health and wealth benefits is a key feature of our strategy,” said Roblin.
The project aims to address a growing demand from the biotechnology industry for fast and robust large-scale proteome analysis to further our understanding of the function and activity of the metabolic network, providing insights into its effect on ageing and age-associated diseases.
“Gaining and sharing knowledge around the ageing process has great potential for unlocking answers to the questions of precision medicine,” said Chris Radloff, Global Vice President & General Manager of the LC–MS Business at Sciex.
The emergence of precision medicine for disease treatment and prevention has highlighted the need for industrialized proteomics, which allows faster analysis of larger sample sets than the current, widely-used omic methods.
The study will be led by Dr. Markus Ralser of the Francis Crick Institute and Professor Kathryn Lilley from the University of Cambridge.
For more information please visit www.sciex.com.
AI and GenAI Applications to Help Optimize Purification and Yield of Antibodies From Plasma
October 31st 2024Deriving antibodies from plasma products involves several steps, typically starting from the collection of plasma and ending with the purification of the desired antibodies. These are: plasma collection; plasma pooling; fractionation; antibody purification; concentration and formulation; quality control; and packaging and storage. This process results in a purified antibody product that can be used for therapeutic purposes, diagnostic tests, or research. Each step is critical to ensure the safety, efficacy, and quality of the final product. Applications of AI/GenAI in many of these steps can significantly help in the optimization of purification and yield of the desired antibodies. Some specific use-cases are: selecting and optimizing plasma units for optimized plasma pooling; GenAI solution for enterprise search on internal knowledge portal; analysing and optimizing production batch profitability, inventory, yields; monitoring production batch key performance indicators for outlier identification; monitoring production equipment to predict maintenance events; and reducing quality control laboratory testing turnaround time.
